Results 281 to 290 of about 202,276 (321)

What to Do When Medical Evidence Can Only Be Generated Through Routine Data: An Example From Pediatric Oncology

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Children undergoing allogeneic stem cell transplantation often receive off‐label rituximab treatment for Epstein–Barr virus reactivation, using adult dosing without pediatric evidence. This project aims to develop a clinical decision support tool (CDSS) that provides evidence‐based dosing scenarios by analyzing real‐world patient data.
Birgit Burkhardt, Antje Walz, Dietrich Knoerzer   +2 more
wiley   +1 more source

Severe Refractory Calcitriol-Mediated Hypercalcemia in Diffuse Large B-Cell Lymphoma Treated With Hemodialysis. [PDF]

JCEM Case Rep
Wu J, Reddy G, Zavgorodneva Z, Hope L.
europepmc   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 422-444, February 2026.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Secondary Acute Myeloid Leukemia in Treatment-Naïve Primary Testicular Diffuse Large B-Cell Lymphoma. [PDF]

Case Rep Hematol
Wan Hanafi HH, Mohd Sabri NM, Muhamat Yusoff R, Nizam Akbar NA, Mohd Noor NH, Hussain FA, Husin A.   +6 more
europepmc   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, -Not available-.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea. [PDF]

Ther Adv Hematol
Kim DH, Kwon S, Cha S, Öz RS, Hong J, Shin DY, Koh Y, Yoon SS, Byun JM.   +8 more
europepmc   +1 more source

Miliary Tuberculosis With Immune Thrombocytopenia in 50‐Year‐Old Ethiopian Woman: A Case Report and Brief Review of Literature

Clinical Case Reports, Volume 14, Issue 2, February 2026.
Diffuse petechiae and non‐palpable purpura (lower extremities below knee, admission photo). ABSTRACT Immune thrombocytopenia (ITP) is a rare but recognized hematologic complication of tuberculosis (TB), particularly miliary TB. We present a case of a 50‐year‐old female with severe thrombocytopenia and hemorrhagic manifestations secondary to miliary TB.
Hayatu Awel Abdela, Tamirat Godebo Woyimo, Ragasa Getachew Bayisa, Sisay Tagese Tafese   +3 more
wiley   +1 more source

Rare Clinical Presentation of Diffuse Large B-Cell Lymphoma as Otitis Media and Mastoiditis. [PDF]

J Audiol Otol
Joo HA, Park HJ.
europepmc   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source